409 related articles for article (PubMed ID: 29903674)
1. Immunogenicity and safety of the adjuvanted recombinant zoster vaccine co-administered with the 23-valent pneumococcal polysaccharide vaccine in adults ≥50 years of age: A randomized trial.
Maréchal C; Lal H; Poder A; Ferguson M; Enweonye I; Heineman TC; Hervé C; Rheault P; Talli J; Wauters D; Oostvogels L
Vaccine; 2018 Jul; 36(29):4278-4286. PubMed ID: 29903674
[TBL] [Abstract][Full Text] [Related]
2. The adjuvanted recombinant zoster vaccine co-administered with a tetanus, diphtheria and pertussis vaccine in adults aged ≥50 years: A randomized trial.
Strezova A; Lal H; Enweonye I; Campora L; Beukelaers P; Segall N; Heineman TC; Schuind AE; Oostvogels L
Vaccine; 2019 Sep; 37(39):5877-5885. PubMed ID: 31443993
[TBL] [Abstract][Full Text] [Related]
3. The adjuvanted recombinant zoster vaccine co-administered with the 13-valent pneumococcal conjugate vaccine in adults aged ≥50 years: A randomized trial.
Min JY; Mwakingwe-Omari A; Riley M; Molo LY; Soni J; Girard G; Danier J
J Infect; 2022 Apr; 84(4):490-498. PubMed ID: 34963639
[TBL] [Abstract][Full Text] [Related]
4. Co-administration of the adjuvanted recombinant zoster vaccine with other adult vaccines: An overview.
Ali SO; Dessart C; Parikh R
Vaccine; 2024 Mar; 42(8):2026-2035. PubMed ID: 38423814
[TBL] [Abstract][Full Text] [Related]
5. Immunogenicity, reactogenicity and safety of 2 doses of an adjuvanted herpes zoster subunit vaccine administered 2, 6 or 12 months apart in older adults: Results of a phase III, randomized, open-label, multicenter study.
Lal H; Poder A; Campora L; Geeraerts B; Oostvogels L; Vanden Abeele C; Heineman TC
Vaccine; 2018 Jan; 36(1):148-154. PubMed ID: 29174683
[TBL] [Abstract][Full Text] [Related]
6. Immunogenicity and safety of concomitant MF59-adjuvanted influenza vaccine and 23-valent pneumococcal polysaccharide vaccine administration in older adults.
Song JY; Cheong HJ; Tsai TF; Chang HA; Choi MJ; Jeon JH; Kang SH; Jeong EJ; Noh JY; Kim WJ
Vaccine; 2015 Aug; 33(36):4647-52. PubMed ID: 25980426
[TBL] [Abstract][Full Text] [Related]
7. Immunogenicity and safety of the adjuvanted recombinant zoster vaccine in patients with solid tumors, vaccinated before or during chemotherapy: A randomized trial.
Vink P; Delgado Mingorance I; Maximiano Alonso C; Rubio-Viqueira B; Jung KH; Rodriguez Moreno JF; Grande E; Marrupe Gonzalez D; Lowndes S; Puente J; Kristeleit H; Farrugia D; McNeil SA; Campora L; Di Paolo E; El Idrissi M; Godeaux O; López-Fauqued M; Salaun B; Heineman TC; Oostvogels L;
Cancer; 2019 Apr; 125(8):1301-1312. PubMed ID: 30707761
[TBL] [Abstract][Full Text] [Related]
8. Immunogenicity and safety of an adjuvanted herpes zoster subunit candidate vaccine in adults ≥ 50 years of age with a prior history of herpes zoster: A phase III, non-randomized, open-label clinical trial.
Godeaux O; Kovac M; Shu D; Grupping K; Campora L; Douha M; Heineman TC; Lal H
Hum Vaccin Immunother; 2017 May; 13(5):1051-1058. PubMed ID: 28068212
[TBL] [Abstract][Full Text] [Related]
9. Immunogenicity and safety of an inactivated quadrivalent influenza vaccine co-administered with a 23-valent pneumococcal polysaccharide vaccine versus separate administration, in adults ≥50years of age: Results from a phase III, randomized, non-inferiority trial.
Ofori-Anyinam O; Leroux-Roels G; Drame M; Aerssens A; Maes C; Amanullah A; Schuind A; Li P; Jain VK; Innis BL
Vaccine; 2017 Nov; 35(46):6321-6328. PubMed ID: 28987445
[TBL] [Abstract][Full Text] [Related]
10. Efficacy, reactogenicity, and safety of the adjuvanted recombinant zoster vaccine for the prevention of herpes zoster in Chinese adults ≥ 50 years: A randomized, placebo-controlled trial.
Alexandra Echeverria Proano D; Zhu F; Sun X; Zoco J; Soni J; Parmar N; Ali SO;
Hum Vaccin Immunother; 2024 Dec; 20(1):2351584. PubMed ID: 38838170
[TBL] [Abstract][Full Text] [Related]
11. Altered immunogenicity of 23-valent pneumococcal polysaccharide vaccine in elderly patients with diabetes who revealed lower responses to concomitant administration of BIKEN varicella zoster vaccine: Results of post hoc analysis of a randomized double-blind trial.
Hata A; Ishioka T; Oishi K; Katayama T; Ohkubo T
J Diabetes Complications; 2019 Mar; 33(3):243-248. PubMed ID: 30579569
[TBL] [Abstract][Full Text] [Related]
12. Safety profile of the adjuvanted recombinant zoster vaccine: Pooled analysis of two large randomised phase 3 trials.
López-Fauqued M; Campora L; Delannois F; El Idrissi M; Oostvogels L; De Looze FJ; Diez-Domingo J; Heineman TC; Lal H; McElhaney JE; McNeil SA; Yeo W; Tavares-Da-Silva F;
Vaccine; 2019 Apr; 37(18):2482-2493. PubMed ID: 30935742
[TBL] [Abstract][Full Text] [Related]
13. Safety and immunogenicity of a Herpes Zoster subunit vaccine in Japanese population aged ≥50 years when administered subcutaneously vs. intramuscularly.
Vink P; Shiramoto M; Ogawa M; Eda M; Douha M; Heineman T; Lal H
Hum Vaccin Immunother; 2017 Mar; 13(3):574-578. PubMed ID: 27936344
[TBL] [Abstract][Full Text] [Related]
14. Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine in adults 18-49 years of age, naive to 23-valent pneumococcal polysaccharide vaccine.
Bryant KA; Frenck R; Gurtman A; Rubino J; Treanor J; Thompson A; Jones TR; Sundaraiyer V; Baxter LM; Gruber WC; Emini EA; Scott DA; Schmoele-Thoma B
Vaccine; 2015 Oct; 33(43):5854-5860. PubMed ID: 26362099
[TBL] [Abstract][Full Text] [Related]
15. Immunogenicity and Safety of the HZ/su Adjuvanted Herpes Zoster Subunit Vaccine in Adults Previously Vaccinated With a Live Attenuated Herpes Zoster Vaccine.
Grupping K; Campora L; Douha M; Heineman TC; Klein NP; Lal H; Peterson J; Vastiau I; Oostvogels L
J Infect Dis; 2017 Dec; 216(11):1343-1351. PubMed ID: 29029122
[TBL] [Abstract][Full Text] [Related]
16. Immunogenicity of simultaneous versus sequential administration of a 23-valent pneumococcal polysaccharide vaccine and a quadrivalent influenza vaccine in older individuals: A randomized, open-label, non-inferiority trial.
Nakashima K; Aoshima M; Ohfuji S; Yamawaki S; Nemoto M; Hasegawa S; Noma S; Misawa M; Hosokawa N; Yaegashi M; Otsuka Y
Hum Vaccin Immunother; 2018; 14(8):1923-1930. PubMed ID: 29561248
[TBL] [Abstract][Full Text] [Related]
17. Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine in adults 70 years of age and older previously vaccinated with 23-valent pneumococcal polysaccharide vaccine.
Jackson LA; Gurtman A; Rice K; Pauksens K; Greenberg RN; Jones TR; Scott DA; Emini EA; Gruber WC; Schmoele-Thoma B
Vaccine; 2013 Aug; 31(35):3585-93. PubMed ID: 23688527
[TBL] [Abstract][Full Text] [Related]
18. Safety Profile of the Adjuvanted Recombinant Zoster Vaccine in Immunocompromised Populations: An Overview of Six Trials.
López-Fauqued M; Co-van der Mee M; Bastidas A; Beukelaers P; Dagnew AF; Fernandez Garcia JJ; Schuind A; Tavares-da-Silva F
Drug Saf; 2021 Jul; 44(7):811-823. PubMed ID: 34115324
[TBL] [Abstract][Full Text] [Related]
19. Immunogenicity of the Adjuvanted Recombinant Zoster Vaccine: Persistence and Anamnestic Response to Additional Doses Administered 10 Years After Primary Vaccination.
Hastie A; Catteau G; Enemuo A; Mrkvan T; Salaun B; Volpe S; Smetana J; Rombo L; Schwarz T; Pauksens K; Hervé C; Bastidas A; Schuind A
J Infect Dis; 2021 Dec; 224(12):2025-2034. PubMed ID: 32502272
[TBL] [Abstract][Full Text] [Related]
20. Immunogenicity and safety of the adjuvanted recombinant zoster vaccine in adults with haematological malignancies: a phase 3, randomised, clinical trial and post-hoc efficacy analysis.
Dagnew AF; Ilhan O; Lee WS; Woszczyk D; Kwak JY; Bowcock S; Sohn SK; Rodriguez Macías G; Chiou TJ; Quiel D; Aoun M; Navarro Matilla MB; de la Serna J; Milliken S; Murphy J; McNeil SA; Salaun B; Di Paolo E; Campora L; López-Fauqued M; El Idrissi M; Schuind A; Heineman TC; Van den Steen P; Oostvogels L;
Lancet Infect Dis; 2019 Sep; 19(9):988-1000. PubMed ID: 31399377
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
